Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
WITHDRAWAL PHENOMENON WITH THE ANTIANDROGEN CASODEX
Autore:
NIEH PT;
Indirizzi:
LAHEY CLIN FDN,MED CTR,DEPT UROL,41 MALL RD BURLINGTON MA 01805
Titolo Testata:
The Journal of urology
fascicolo: 3, volume: 153, anno: 1995,
parte:, 2
pagine: 1070 - 1072
SICI:
0022-5347(1995)153:3<1070:WPWTAC>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
FLUTAMIDE WITHDRAWAL; PROSTATE-CANCER; CARCINOMA; CELLS;
Keywords:
PROSTATIC NEOPLASMS; ANDROGEN ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME;
Tipo documento:
Note
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
11
Recensione:
Indirizzi per estratti:
Citazione:
P.T. Nieh, "WITHDRAWAL PHENOMENON WITH THE ANTIANDROGEN CASODEX", The Journal of urology, 153(3), 1995, pp. 1070-1072

Abstract

Total androgen blockade with castration and antiandrogens has become the primary therapy in metastatic prostate carcinoma. Several reports have been published on the flutamide withdrawal syndrome with a favorable response in patients with progression of disease after lengthy remission while taking combined hormone therapy. The experience with withdrawal of the experimental nonsteroidal antiandrogen casodex dagger in3 patients is reported. All patients received casodex monotherapy initially, then luteinizing hormone-releasing hormone analogues were added on progression of disease (bone scan and prostate specific antigen [PSA]) and eventually casodex was withdrawn on further progression of disease (PSA and bone scan). Two patients had declines in PSA levels of42% and 75% sustained for 3 to 6 months, and 1 patient had a stable condition for 2 months. These responses were similar to those of withdrawal of flutamide, which were limited to patients who had received combination therapy at the onset of treatment. Thus, the observations in this report would suggest that the initial and sustained exposure to an antiandrogen is the more important factor in the withdrawal phenomenon rather than the low androgen environment alone that occurs with initial luteinizing hormone-releasing hormone analogue monotherapy, orchiectomy or combination luteinizing hormone-releasing hormone analogue and antiandrogen.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 02/04/20 alle ore 02:26:34